Ashish A Deshmukh1,2,3, Hui Zhao1, Luisa Franzini4, David R Lairson2, Elizabeth Y Chiao5, Prajnan Das6, Michael D Swartz2, Sharon H Giordano1, Scott B Cantor1. 1. Departments of Health Services Research. 2. The University of Texas Health Science Center of Houston School of Public Health. 3. Cancer Prevention Training Research Program, The University of Texas MD Anderson Cancer Center. 4. Department of Health Services Administration, University of Maryland School of Public Health, College Park, MD. 5. Department of Medicine, Section of Infectious Disease, Baylor College of Medicine, Houston, TX. 6. Radiation Oncology.
Abstract
OBJECTIVE: To determine the lifetime and phase-specific cost of anal cancer management and the economic burden of anal cancer care in elderly (66 y and older) patients in the United States. PATIENTS AND METHODS: For this study, we used Surveillance Epidemiology and End Results-Medicare linked database (1992 to 2009). We matched newly diagnosed anal cancer patients (by age and sex) to noncancer controls. We estimated survival time from the date of diagnosis until death. Lifetime and average annual cost by stage and age at diagnosis were estimated by combining survival data with Medicare claims. The average lifetime cost, proportion of patients who were elderly, and the number of incident cases were used to estimate the economic burden. RESULTS: The average lifetime cost for patients with anal cancer was US$50,150 (N=2227) (2014 US dollars). The average annual cost in men and women was US$8025 and US$5124, respectively. The overall survival after the diagnosis of cancer was 8.42 years. As the age and stage at diagnosis increased, so did the cost of cancer-related care. The anal cancer-related lifetime economic burden in Medicare patients in the United States was US$112 million. CONCLUSIONS: Although the prevalence of anal cancer among the elderly in the United States is small, its economic burden is considerable.
OBJECTIVE: To determine the lifetime and phase-specific cost of anal cancer management and the economic burden of anal cancer care in elderly (66 y and older) patients in the United States. PATIENTS AND METHODS: For this study, we used Surveillance Epidemiology and End Results-Medicare linked database (1992 to 2009). We matched newly diagnosed anal cancerpatients (by age and sex) to noncancer controls. We estimated survival time from the date of diagnosis until death. Lifetime and average annual cost by stage and age at diagnosis were estimated by combining survival data with Medicare claims. The average lifetime cost, proportion of patients who were elderly, and the number of incident cases were used to estimate the economic burden. RESULTS: The average lifetime cost for patients with anal cancer was US$50,150 (N=2227) (2014 US dollars). The average annual cost in men and women was US$8025 and US$5124, respectively. The overall survival after the diagnosis of cancer was 8.42 years. As the age and stage at diagnosis increased, so did the cost of cancer-related care. The anal cancer-related lifetime economic burden in Medicare patients in the United States was US$112 million. CONCLUSIONS: Although the prevalence of anal cancer among the elderly in the United States is small, its economic burden is considerable.
Authors: Angela B Mariotto; K Robin Yabroff; Yongwu Shao; Eric J Feuer; Martin L Brown Journal: J Natl Cancer Inst Date: 2011-01-12 Impact factor: 13.506
Authors: H M Truong; H-H M Truong; T Kellogg; J D Klausner; M H Katz; J Dilley; K Knapper; S Chen; R Prabhu; R M Grant; B Louie; W McFarland Journal: Sex Transm Infect Date: 2006-12 Impact factor: 3.519
Authors: Carol E DeSantis; Chun Chieh Lin; Angela B Mariotto; Rebecca L Siegel; Kevin D Stein; Joan L Kramer; Rick Alteri; Anthony S Robbins; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2014-06-01 Impact factor: 508.702
Authors: Michael E Stokes; Jack Ishak; Irina Proskorovsky; Libby K Black; Yijian Huang Journal: BMC Health Serv Res Date: 2011-12-28 Impact factor: 2.655
Authors: Ashish A Deshmukh; Elizabeth Y Chiao; Scott B Cantor; Elizabeth A Stier; Stephen E Goldstone; Alan G Nyitray; Timothy Wilkin; Xiaojie Wang; Jagpreet Chhatwal Journal: Cancer Date: 2017-09-26 Impact factor: 6.860
Authors: Alan G Nyitray; Joseph T Hicks; Lu-Yu Hwang; Sarah Baraniuk; Margaret White; Stefanos Millas; Nkechi Onwuka; Xiaotao Zhang; Eric L Brown; Michael W Ross; Elizabeth Y Chiao Journal: Sex Transm Infect Date: 2017-08-23 Impact factor: 3.519
Authors: Jean-François Laprise; Harrell W Chesson; Lauri E Markowitz; Mélanie Drolet; Dave Martin; Élodie Bénard; Marc Brisson Journal: Ann Intern Med Date: 2019-12-10 Impact factor: 25.391
Authors: Ryan Suk; Parag Mahale; Kalyani Sonawane; Andrew G Sikora; Jagpreet Chhatwal; Kathleen M Schmeler; Keith Sigel; Scott B Cantor; Elizabeth Y Chiao; Ashish A Deshmukh Journal: JAMA Netw Open Date: 2018-09-07
Authors: Kaustuv Bhattacharya; John P Bentley; Sujith Ramachandran; Yunhee Chang; Benjamin F Banahan; Ruchit Shah; Nickhill Bhakta; Yi Yang Journal: JAMA Netw Open Date: 2021-07-01